Improved biotech stock performance translated into an uptick in public financings, but private money and partnership dollars slipped. Excluding partnership monies, industry raised $6.9 billion in public equity and debt financings, an increase of 61% over 1Q16. Although private money dipped from a 1Q16 peak of $4 billion to $3.1 billion, it is still on course for its best-ever year. Partnership money ($13.1 billion) declined for the third consecutive quarter, representing a 24% drop from 1Q16.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Edelson, S., Wolfe, M. 2Q16—biotech claws back. Nat Biotechnol 34, 800 (2016). https://doi.org/10.1038/nbt.3654
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3654